Immunomax, which participated in MIK Hot Spot (Made in Korea Online Exhibition) KHIDI introduced its self-memory T cell-based anti-cancer immune cell treatment drug and virus vaccine high-efficiency production animal cell line improvement technology.
Hello, this is Park Se-ho Ho, CEO of Immunomax. Immunomax is a company that develops biopharmaceuticals based on immune system regulation. I have been studying virus vaccines and anti-cancer drugs for more than 20 years at Korea University, and I would like to contribute to overcoming diseases by developing accumulated technologies as biopharmaceuticals.
Background for Development and Product Competitiveness 1 – Virus vaccine high-efficiency production animal cell line technology
To produce the virus vaccine highly efficiently, Immunomax selected specific genes related to productivity through big data analysis. Through genetic manipulation, it has established a platform technology that can produce 2-3 times more virus vaccines or antibodies than existing animal cell lines. This technology is an important technology that can quickly respond to the outbreak of a pandemic virus such as COVID-19, and is an excellent platform technology that enables rapid and mass production of treatment drugs. Cell lines with technology have the same effect as conventional vaccines and are highly productive at the same time. We have eight domestic and foreign patents on this technology to secure and protect our technology.
Background for Development and Product Competitiveness 2 – Anti-cancer immuno-memory T cell treatment drug
Immunmax’s second flagship product is the anti-cancer immune cell therapy. Conventional immune T cell treatment drugs have little or no effect, and if they are good, they cause side effects such as cytokine storms, and have safety problems. As a way to solve this problem, using the memory T cells is known to be effective, but it had not been successfully commercialized. We Immunomax have secured memory T cell enhancement technology through basic research for a long time, so we are developing treatment drugs to maximize treatment effects and minimize side effects. The anti-cancer effects have been confirmed in animal models.
Immunomax is located in Korea University Industry-University Building, and has successfully accumulated approximately 8 billion won in investment since its establishment in October 2015. It is a R&D company with 13 experts composed of Master’s degree in relevant studies. Park Se-ho is a professor at Korea University who is an expert in immunology with 18 patents registered and presented and 77 papers published.
Expansion: Market Entry Strategy (Marketing)
We intend to actively promote technology and products at home and abroad through clinical research papers and conferences/exhibitions, and make new sales channels with technology transfer and copyright agreements. In the case of the domestic market, we have a strategy to seek market entry through cooperation with companies with nationwide sales networks.
Performance and Investment Issues
The foundation for the commercialization of cell treatment drugs has been built with 2019 Startup Leap Project, and we aim to begin the clinical trial on the immune cell treatment drugs on 2021 and be listed on KOSDAQ in 2023. We would like to grow as a major company of K-Bio by treating incurable diseases such as cancer and autoimmune diseases and developing vaccines and treatment drugs for infectious diseases by controlling immunity. Contact Number: 02-6946-8700 / Email: email@example.com
The products and services of the major companies of KHIDI Health Industry Startup Innovation Center in the MIK Hot Spot (Made in Korea Online Exhibition) will also be displayed in BIO KOREA 2020. Asia’s biggest bio convention BIO KOREA 2020 co-organized by KHIDI and Chungbuk Province and sponsored by MOHW will be open online due to the COVID-29 pandemic on May 18-23. Virtual exhibition halls, conference, and business forums will be operated, and the companies will be promoting their competitiveness. Also, with video meetings, businesses between overseas speakers, buyers, and domestic and foreign participating companies will be made. To date, more than 160 companies have applied for the virtual exhibition booth at BIO KOREA 2020. Companies wishing to participate can apply through the web page or email by Apr. 30.
The global news network AVING News has begun holding the MIK Hot Spot (Made in Korea Online Exhibition) to help small and medium-sized companies enter the market and attract investment 365 days a year. AVING News has been running online exhibitions since 2005 and had 975 online exhibitions so far. Its YouTube online exhibition has placed itself as Korea’s largest online exhibition hall that opens with 19,000 videos (booths) with more than 800,000 visits per month which means more than 10 million visits per year.
The MIK Hot Spot online exhibition is scheduled to be held regularly according to the field, target market, and participating institutions, and it will be presented as a new type of online business by transforming the know-hows and values of the participating companies according to the trend. Companies that want to participate can apply and apply through the marketing support projects from supporting institutions in the local governments. Refer to the institutions for more information.tecaving2020-06-18T05:43:59+00:00